Frederik Bangnowski

Boehringer Ingelheim Pharma GmbH and Co. KG

Frederik Bangnowski is listed at Boehringer Ingelheim Pharma GmbH and Co. KG. Frederik is scheduled to speak at SLAS 2027 International Conference & Exhibition on 3 February 2027.

Compiled from published conference agendas; not yet confirmed by Frederik. Is this you? Claim this profile.

About

Frederik Bangnowski is a PhD Candidate at Goethe University Frankfurt in collaboration with Boehringer Ingelheim, where his research focuses on the evaluation of novel assay technologies to advance large‑scale GPCR in‑vitro pharmacology. Alongside his scientific work, he serves as a representative of the Boehringer-Ingelheim PhD community, actively fostering collaboration and communication within the research environment. His previous professional experience spans multiple pharmaceutical companies, providing him with hands‑on expertise in laboratory automation, analytical development, pharmaceutical production, and GxP‑compliant quality control.

Upcoming

SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027

A Label-Free RTCA Platform for GPCR Hit Discovery and Orthogonal Hit Validation Speaker · 3 February 2027